Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy
Giuseppe Cabibbo(Department of Health), on behalf of the M. D. T. Project Working Group, Ciro Celsa(Department of Health), Caterina Cocuzza(Ospedale Garibaldi), Piera Federico, Luca Pinto(University of Bologna), F. Cartabellotta(Ospedale Buccheri la Ferla Fatebenefratelli), Raffaella Tortora, Maurizio Russello(Ospedale Garibaldi), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Giovanni Galati(Università Campus Bio-Medico), Maria Rosaria Attanasio(Ospedale Antonio Cardarelli), Laura Schiadà, MariaFiorella Brangi(Ospedale Antonio Cardarelli), Marianna Silletta(Università Campus Bio-Medico), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mauro Piccirillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Martina Assanti, Gianluca Svegliati Baroni(Marche Polytechnic University), Salvatore Gruttadauria(University of Catania), Bruno Daniele(Ospedale D. Cotugno), Roberto Bordonaro(Ospedale Garibaldi), Giovan Giuseppe Di Costanzo(Ospedale Antonio Cardarelli), Francesco Izzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Nappi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppina Pacella(Università Campus Bio-Medico), Rossana Berardi(Marche Polytechnic University), Giada Lodolo, Desiree Lucy Anna Rita Caudullo(Ospedale Garibaldi), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Francesco Deligios, Emiliano Tamburini(Ospedale Infermi di Rimini)
Cited by 0
Related Papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
|The Lancet Oncology|2022|268
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
|The Lancet. Gastroenterology & hepatology|2024|245